Načítá se...
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
Advanced bladder cancer patients have limited therapeutic options resulting in a median overall survival (OS) between 12 and 15 months. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) has been used successfully in treating patients with metastatic melanoma, resulting in a medi...
Uloženo v:
| Vydáno v: | Oncoimmunology |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6140546/ https://ncbi.nlm.nih.gov/pubmed/30228944 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1476816 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|